



HOUSE BILL 325: Opioid Epidemic Response Act.

2019-2020 General Assembly

Committee:	Senate Health Care. If favorable, re-refer to Rules and Operations of the Senate	Date:	June 18, 2019
Introduced by:	Reps. Dobson, White, Barnes, Black	Prepared by:	Jessica Boney
Analysis of:	PCS to Second Edition H325-CSBC-51		Staff Attorney

OVERVIEW: *The Proposed Committee Substitute (PCS) to House Bill 325 removes the registration requirement for buprenorphine prescribers, decriminalizes the use of drug testing equipment, broadens the objectives of syringe exchange programs, and removes the restriction on using State funds to purchase certain supplies.*

BILL ANALYSIS:

The PCS to House Bill 325 does the following:

Part I eliminates the state registration requirement for buprenorphine prescribers.

Part II decriminalizes drug testing equipment used to detect contaminants in controlled substances.

Part III adds reducing the number of drug overdoses in the State to the objectives of syringe exchange programs and removes the restriction on the use of State funds to purchase needles, hypodermic syringes, or other injection supplies.

EFFECTIVE DATE: This act is effective when it becomes law.

Karen Cochrane-Brown
Director



Legislative Analysis
Division
919-733-2578